▲ +10.21% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for PMV Pharmaceuticals in the last 3 months. The average price target is $38.00, with a high forecast of $42.00 and a low forecast of $34.00. The average price target represents a 10.21% upside from the last price of $34.48.
The current consensus among 4 polled investment analysts is to buy stock in PMV Pharmaceuticals.
PMV Pharmaceuticals, Inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.